The primary focus of this proposal is to extend our current studies designed to examine the role of the polymorphonuclear leukocytes (PMN), oxygen radicals and metabolites of arachidonic acid as mediators of cell injury associated with myocardial ischemia and/or myocardial reperfusion. Studies will be conducted in the anesthetized dog subjected to temporary left circumflex coronary artery occlusion followed by reperfusion and the heart later subjected to a quantitative assessment of irreversible ischemic myocardial damage. The interventions to be examined include depletion of PMN's by anti-neutrophil antibodies, enzymatic degradation of oxygen radicals by superoxide dismutase and catalase, and pharmacologic inhibitors of phospholipase and of lipoxygenase and/or cyclooxygenase. The effects of selected interventions will be assessed in terms of infarct size, neutrophil infiltration of ischemic myocardium, functional integrity of ischemic microvasculature, regional blood flow, ventricular function and ultimate healing. Infarct size and the anatomic area a risk will be determined by a dual staining technique. PMN infiltration will be assessed using autologous 111-indium labeled leukocytes. Permeability changes within the microvasculature will be assessed with the use of 125-iodine labeled albumin. Regional myocardial blood flow will be determined with the use of radiolabeled microspheres. Segmental contractile function will be assessed with the use of intramyocardial ultrasonic crystals, both acutely and chronically. Infarct healing will be graded by determination of scar thickness and histological evaluation. The object of these studies will be to determine whether modification of leukocyte function, scavaging of free radicals or alterations of arachidonic acid metabolism will favorably alter the effects of reperfusion upon ischemic myocardium, thus, reducing that component of myocardial injury associated with coronary reperfusion. The results of this study should enhance our understanding of the cytotoxic role of the leukocyte in myocardial ischemia and/or reperfusion injury. The outcome could lead to the development of improved pharmacologic interventions to protect the heart subject to reperfusion as with thrombolytic therapy or after the termination of global-ischemic arrest during cardiopulmonary by-pass.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL019782-10
Application #
3335950
Study Section
Cardiovascular Study Section (CVA)
Project Start
1977-01-01
Project End
1990-03-31
Budget Start
1988-04-01
Budget End
1989-03-31
Support Year
10
Fiscal Year
1988
Total Cost
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Type
Schools of Medicine
DUNS #
791277940
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Kilgore, K S; Tanhehco, E J; Park, J L et al. (1998) Reduction of myocardial infarct size in vivo by carbohydrate-based glycomimetics. J Pharmacol Exp Ther 284:427-35
Black, S C; Driscoll, E M; Lucchesi, B R (1998) Effect of ramiprilat or captopril on myocardial infarct size: assessment in canine models of ischemia alone and ischemia with reperfusion. Pharmacology 57:35-46
Park, J L; Tanhehco, E J; Kilgore, K S et al. (1997) Reviparin-sodium prevents complement-mediated myocardial injury in the isolated rabbit heart. J Cardiovasc Pharmacol 30:658-66
Rebello, S S; Driscoll, E M; Lucchesi, B R (1997) TP-9201, a glycoprotein IIb/IIIa platelet receptor antagonist, prevents rethrombosis after successful arterial thrombolysis in the dog. Stroke 28:1789-96
Rebello, S S; Miller, B V; Basler, G C et al. (1997) CVS-1123, a direct thrombin inhibitor, prevents occlusive arterial and venous thrombosis in a canine model of vascular injury. J Cardiovasc Pharmacol 29:240-9
Rebello, S S; Blank, H S; Rote, W E et al. (1997) Antithrombotic efficacy of a recombinant nematode anticoagulant peptide (rNAP5) in canine models of thrombosis after single subcutaneous administration. J Pharmacol Exp Ther 283:91-9
Gralinski, M R; Wiater, B C; Assenmacher, A N et al. (1996) Selective inhibition of the alternative complement pathway by sCR1[desLHR-A] protects the rabbit isolated heart from human complement-mediated damage. Immunopharmacology 34:79-88
Sudo, Y; Lucchesi, B R (1996) Antithrombotic effect of GYKI-14766 in a canine model of arterial and venous rethrombosis: a comparison with heparin. J Cardiovasc Pharmacol 27:545-55
Gralinski, M R; Black, S C; Stancato, L F et al. (1996) Heat stress protects the perfused rabbit heart from complement-mediated injury. Am J Physiol 271:H571-8
Cousins, G R; Friedrichs, G S; Sudo, Y et al. (1996) Orally effective CVS-1123 prevents coronary artery thrombosis in the conscious dog. Circulation 94:1705-12

Showing the most recent 10 out of 78 publications